Novartis is licensing an mRNA-based therapy designed to produce a CD3xCD19 T cell engager inside the body. Abogen Biosciences says the in vivo approach could reduce the likelihood of dangerous cytokine release.
Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen